🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 45 of 857 · Phase 3 first, then by program name

  1. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  2. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

  3. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  4. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  5. Cladribine (MAVENCLAD®)

    United Therapeutics Europe Ltd

    Advanced Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  6. Clamp-Crushing technique

    The First People's Hospital of Lianyungang

    Hepatobiliary Disease

    phase 3 other completed

    1 trial

  7. Clascoterone

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acne Vulgaris

    phase 3 small molecule active

    1 trial

  8. Claseprubart

    Dianthus Therapeutics, Inc. /DE/

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

  9. Class I or III Antiarrhythmic Medications

    Rhythm Pharmaceuticals Netherlands B.V.

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  10. Clazakizumab

    CSL Behring GmbH

    Antibody-mediated Rejection

    phase 3 mab terminated

    1 trial

  11. Clemizole HCl

    Harmony Biosciences Holdings

    Lennox Gastaut Syndrome

    phase 3 small molecule active

    1 trial

  12. Clemizole HCl

    Harmony Biosciences Holdings

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

  13. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

  14. Clifutinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Leukemia, Acute Myeloid (AML)

    phase 3 small molecule active

    1 trial

  15. Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

    Alphapharm Pty Ltd

    Chronic stable plaque psoriasis

    phase 3 other active

    1 trial

  16. Clonidine HCL

    BRIGHT MINDS BIOSCIENCES INC.

    Neonatal Abstinence Syndrome

    phase 3 small molecule completed

    2 trials

  17. Clonidine HCl Mucoadhesive Buccal Tablet

    Monopar Therapeutics

    Chemoradiotherapy-Induced Severe Oral Mucositis

    phase 3 small molecule terminated

    1 trial

  18. Clopidogrel

    Eli Lilly and Company

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial

  19. Cloxacilin

    Lxo Ireland Designated Activity Company

    Staphylococcus

    phase 3 small molecule terminated

    1 trial

  20. Co-Trimoxazole 960Mg Dispersible Tablet

    United Therapeutics Europe Ltd

    Spontaneous Bacterial Peritonitis

    phase 3 small molecule active

    1 trial

  21. Coagulation Factor VIIa (Recombinant)

    Laboratoire HRA Pharma

    Hemophilia

    phase 3 mab terminated

    1 trial

  22. Coenzyme Q10 and Lisinopril

    United Therapeutics Europe Ltd

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    1 trial

  23. Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  24. Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Stress Disorders, Post-Traumatic

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources